Daily Top 50 Gainers & Losers

Market Regime — the colored bar under each day is the market's overall “weather,” scored from the indexes (trend, fear/VIX, small-cap breadth). It's market-wide context, not a stock pick: even a great company gets dragged down in a red tape. Read it to gauge when to lean in vs. wait for calmer water — click any day for the full read.

Risk-On · supportive Neutral Risk-Off · headwind Stress · fear

Market Recap · Wednesday, September 30, 2026

Snapshot: Sep 30, 2026 · 5:00 PM 100 stocks analyzed

Down Day

Wed, Sep 30, 2026 Broad Selloff Normal

Broad selloff grips equities as Russell 2000 leads downside with -1.47%, offsetting isolated micro-cap rallies in healthcare and biotech, with fear metrics ticking higher.

60% Broad-based selloff across all major indices, with the Russell 2000 falling 1.47%, S&P 500 down 0.71%, and Nasdaq off 0.28%, signaling a risk-off environment despite contained VIX uptick of 4.3%. Mid-cap weakness (S&P 400 -1.55%) underscores rotation away from growth-dependent equities.
25% Healthcare sector paradoxically dominated both gainers and losers, claiming 35% of top risers yet also 31% of top decliners, with blockbuster movers like TGE (+90% on 10-fold profit surge) and PACB (+29% on $27M DoD contract) offset by clinical setbacks: RFL crashed 35% after Phase 3 failure in Niemann-Pick disease therapy, and CVRX fell 34% despite late-breaking trial data at HFSA.
15% Micro-cap volatility and dispersion remain elevated despite "normal" classification, with SHOT plummeting 80% on undisclosed catalyst and 5 debutant names returning to gainers list after absences, suggesting retail-driven trading and warrant/rights expirations are the only tactical winners in an otherwise defensive tape.

Healthcare drove 35% of gainers 5 names returned after long absences NCT · 3-day losers streak XHLD · 3-day losers streak CTNM — first appearance LPA — first appearance

Market Regime

Wed, Sep 30, 2026 Neutral conf: medium macro · prototype

-9

Neutral −100 … +100 · + tailwind / − headwind

VIX16.3 p48 Drawdown-1.9% Held6d · building SinceSep 23

Top drivers: Small-cap leadership ▼ S&P drawdown (60d) ▲ VIX 5d momentum ▼

processId: history-market-regime

Market Indexes

Wed, Sep 30, 2026 13

S&P 500

7,651.54

−54.49

-0.71%

Dow Jones

50,906.05

−605.54

-1.18%

NASDAQ Composite

26,861.06

−74.98

-0.28%

NASDAQ 100

30,408.50

−61.79

-0.20%

DJ US Total Market

75,374.36

−613.58

-0.81%

Russell 1000

4,155.76

−33.41

-0.80%

S&P MidCap 400

3,595.97

−56.77

-1.55%

Russell 2000

2,796.86

−41.80

-1.47%

Russell 2500

1,199.73

−6.40

-0.53%

Russell 3000

4,327.40

−35.97

-0.82%

Nasdaq Financial-100

7,214.75

−78.40

-1.08%

NIFTY 50

22,620.45

−442.65

-1.92%

VIX

16.34

+0.67

+4.28%

Biggest Gainers

Wed, Sep 30, 2026 50

TGE

Tallgrass Energy LPFinancial Services

$1.54+$0.77

+90.1%

NYSE · Mkt cap $44 M

TGE's stock surged 90% following a report that its profit increased nearly 10-fold, with total assets reaching $1.8 billion and net assets at $932 million, signaling a major earnings or financial milestone.

The headline explicitly states that TGE's profit surged by 9.9 times, a dramatic earnings expansion that would justify a sharp single-day rally in any equity. The company also reported substantial asset growth to $1.8 billion total and $932 million in net assets, indicating balance sheet strengthening. The news appears to be a financial results announcement or update. However, the headline snippet is incomplete and lacks critical context such as the prior-year or prior-quarter baseline, the period covered by this earnings surge, whether this beat or matched expectations, or the specific business drivers behind the profit explosion. The company description identifies TGE as jointly established by AMTD Group and related entities, which may carry additional investor sentiment or momentum factors. Without the full earnings release or investor guidance, we cannot rule out that market conditions or technical factors also amplified the move, but the profit surge is the most concrete catalyst named.

TWLVR

Twelve Seas Investment Company III Rights

$0.13+$0.05

+73.0%

NASDAQ

No news headlines were found in the last 48 hours, but the 73% gain in this rights offering security likely reflects either a technical bounce in a low-price microcap, news that failed to appear in the RSS feed, or positive momentum in the underlying SPAC.

Twelve Seas Investment Company III Rights is a SPAC rights offering, a security category known for high volatility at low price points where small absolute dollar moves translate to large percentage swings. The absence of any news in the Yahoo Finance RSS feed over the last 48 hours is notable and suggests either that no material announcement occurred, or that relevant news did not surface in that particular data source. Rights offerings are particularly sensitive to sentiment shifts around the parent SPAC's prospects, potential mergers, or redemption dynamics. Without evidence of a specific catalyst, the move is most likely attributable to technical factors common to microcap securities (algorithmic rebalancing, retail attention, short covering), or to a news event that simply did not appear in the headlines provided.

EURKR

Eureka Acquisition Corp Right

$0.41+$0.16

+62.1%

NASDAQ

No news headlines were available in the last 48 hours to explain EURKR's 62% gain, but the sharp jump in a SPAC rights security suggests either technical repricing, a delayed news flow update, or trader activity tied to the underlying SPAC warrant or merger dynamics.

Eureka Acquisition Corp Right is a SPAC-related security, and the absence of any news headlines over the last two days makes it difficult to pinpoint a specific catalyst. However, rights offerings and SPAC securities are prone to sudden repricing based on several factors: shifts in the underlying SPAC's merger negotiations or announcement timing, changes in warrant or rights valuation relative to redemption activity, technical or algorithmic trading in low-liquidity securities, or delayed reporting of news that occurred slightly outside the 48-hour window. Rights securities are typically illiquid and thin, so even modest order flow can drive large percentage moves. Without concrete news, the jump most likely reflects either internal SPAC-related developments not yet reflected in headline feeds or pure technical trading momentum in a highly volatile, low-float security.

HEPA

Hepion Pharmaceuticals IncHealthcare

$0.10+$0.04

+55.5%

NASDAQ · Mkt cap $5.5 M

No news headlines were found in the last 48 hours, so the 55.52% jump in HEPA stock cannot be directly attributed to a published announcement. The move likely reflects either a technical bounce in a micro-cap biotech, short covering, or an untracked development.

Hepion Pharmaceuticals is a small-cap biotech stock trading at $0.10 per share, which typically characterizes a distressed or early-stage company. The absence of any recent news headlines in the 48-hour window preceding this substantial single-day gain is notable. For penny-stock biotechs, large percentage moves are common and can occur from several sources: technical rebounds after oversold conditions, short squeeze activity given typically high short interest in distressed stocks, clinical trial data releases that may not immediately appear in major financial news feeds, insider transactions, or market rumors spreading through retail trading channels. Without confirmatory headlines from Yahoo Finance RSS or other major sources, the specific catalyst remains unidentified. The stock's rank as the 4 gainer suggests broad market attention, but that attention may be disconnected from any formal corporate announcement.

TNON

Tenon Medical, Inc.Healthcare

$4.08+$1.38

+50.5%

NASDAQ · Mkt cap $2.4 M

Tenon Medical announced the full commercial launch of its SImmetry+ SI joint fusion system, which generated $1.2 million in revenue during alpha testing, driving a 50% gain as investors react to validated demand and expansion plans.

The headline establishes a concrete product milestone: the SImmetry+ system completed alpha launch and is now in full commercial rollout. The $1.2 million in incremental revenue during the limited launch period provides tangible proof of market traction in a medical device category (SI joint fusion) with significant addressable market potential. The announcement of plans to expand instrument sets and support anticipated demand suggests management confidence in customer adoption and capacity planning. For a smaller medical device company, a successful product launch with early revenue validation often signals a significant inflection point and can justify material stock repricing. The timing and specificity of the news align directly with the magnitude of the gain.

ZZZTT

ETF

$1.21+$0.39

+47.6%

GTERR

Globa Terra Acquisition Corporation Rights

$0.07+$0.01

+29.5%

FNGR

FingerMotion, Inc.Communication Services

$0.18+$0.04

+29.4%

NASDAQ · Mkt cap $14 M

FingerMotion announced a definitive agreement to acquire Newbit Technology and its 9.9 MW powered data center site for $2.3 million, a material crypto-infrastructure asset that likely triggered the 29% jump.

On September 29, FingerMotion disclosed a definitive share purchase agreement to acquire 100% of Newbit Technology, which operates a powered data center site in County of Newell with 9.9 MW capacity. The deal is structured as a cash consideration of $2.3 million on a cash-free, debt-free basis, with closing targeted for on or before October. For a micro-cap stock trading at $0.18, this represents a concrete acquisition of operating infrastructure in the cryptocurrency or blockchain computing space. The announcement of a definitive agreement (versus preliminary or binding commitment) and the specific MW capacity and location details suggest material operational value. The 29% intraday move reflects investor enthusiasm about the company adding tangible power infrastructure assets, which is typically viewed as a positive strategic development for blockchain-focused companies.

PACB

Pacific Biosciences of California IncHealthcare

$2.37+$0.53

+28.9%

NASDAQ · Mkt cap $472 M

Pacific Biosciences stock surged 28.88% following news that genomics provider Sampled secured a five-year contract worth up to $27.1 million from the U.S. Department, a significant deal that likely drove institutional and retail buying interest.

The primary headline from September 29 documents that PACB jumped 5.8% in afternoon trading after Sampled announced a $27.1 million five-year U.S. government contract. While the headline does not explicitly state PACB is Sampled or owns Sampled, the context of PACB being described as a "genomics provider" paired with Sampled's announcement suggests a direct business relationship or acquisition that would benefit PACB's revenue or validates its market position. The second headline confirms PACB made "big moves yesterday" but provides no additional detail. The 28.88% total gain across the snapshot period substantially exceeds the 5.8% intraday move mentioned, suggesting either continued buying momentum into the next session, late-arriving news interpretation, or a compounding of positive sentiment. Without clarification on PACB's exact relationship to Sampled or the contract terms, some inference is required, but a major government contract in genomics would be a material positive for a company in that sector.

EONR.WT

EON Resources Inc WT

$0.10+$0.02

+24.4%

FMACR

Future Money Acquisition Corporation Rights

$0.15+$0.03

+24.2%

NASDAQ

No news headlines were found in the last 48 hours; the 24% gain in this rights offering is most likely due to technical factors, retail trader activity, or delayed market reaction to an untracked event.

FMACR is a SPAC rights offering, a security class known for high volatility and sensitivity to sentiment around the underlying acquisition target and broader SPAC market conditions. No substantive news appeared in the Yahoo Finance RSS feed in the 48 hours preceding this jump, which means the catalyst is not immediately identifiable from major press releases or earnings announcements. Rights offerings in the SPAC space can move sharply on technical factors such as expiration dates, redemption thresholds, or changes in the probability of deal completion, as well as on retail trading interest or broader sector momentum shifts. Without access to real-time order flow, social media chatter, or the specific terms of FMACR's exercise window, we cannot pinpoint the precise trigger.

GURE

Gulf Resources Inc

$3.18+$0.70

+24.1%

GRAN

Grande Group LimitedFinancial Services

$1.09+$0.21

+24.0%

NASDAQ · Mkt cap $31 M

No news headlines were found in the last 48 hours for GRAN, so the 24% gain cannot be attributed to a specific announced event; the move likely reflects technical trading, delayed news, or sentiment shift that is not yet visible in the headlines provided.

The absence of recent news headlines creates a clear information gap. A single-day 24% jump on no identifiable news is unusual and suggests either that the catalyst exists but has not yet been indexed by the news feed provided, or that the move is driven by technical factors such as short covering, options expiry, or a delayed market reaction to an earlier announcement. For a micro-cap or lower-liquidity name like GRAN trading at $1.09, such moves can also be amplified by thin volume. Without access to the company's investor relations channels, SEC filings, or real-time market data, it is not possible to determine whether the jump reflects positive fundamentals, a rumor, or pure technicals. Any explanation at this stage is speculation.

ALISR

Calisa Acquisition Corp Right

$0.83+$0.16

+23.9%

NASDAQ

No news headlines were available in the last 48 hours to explain the 23.88% gain in ALISR. The move likely reflects typical SPAC rights volatility or a delayed news event not yet captured by the feed.

Calisa Acquisition Corp Right is a SPAC rights instrument, a derivative security whose value depends on the underlying SPAC's merger prospects and redemption dynamics. Because no news appeared in the provided 48-hour window, the catalyst for today's spike is not directly identifiable from the sources given. SPAC rights can move sharply on speculation about merger timelines, redemption levels, or technical factors like options expiration or short-covering. The absence of headlines suggests either the move was driven by intra-SPAC momentum unrelated to fresh news, or a news event occurred outside the monitored news feed window. Without additional context on the SPAC's current merger status or recent investor activity, attributing the move to a specific event would be speculation.

CTNM

Contineum Therapeutics, Inc. Class A Common Stock

$13.42+$2.58

+23.8%

ARCLR

ARC Group Acquisition I Corp Right

$0.21+$0.04

+23.4%

RBOT

D8 Holdings Corp.Healthcare

$0.08+$0.01

+22.9%

NYSE · Mkt cap $257 K

No news headlines were found in the last 48 hours, so the 22.89% gain cannot be attributed to a published catalyst. The move likely reflects technical trading, delayed news dissemination, or market rumors in a very low-priced micro-cap stock.

D8 Holdings Corp. trades at just $0.08 per share with no recent news coverage on Yahoo Finance, making it difficult to pinpoint a specific catalyst for today's 22.89% surge. Stocks at this price level typically experience outsized percentage moves on relatively small absolute share purchases, which can amplify volatility. The absence of news suggests either technical factors such as short covering or algorithmic trading, a delayed announcement not yet indexed by major news feeds, unverified social media circulation, or general micro-cap momentum trading. Without access to after-hours news, SEC filings, or real-time rumor tracking, any specific explanation would be speculative. Very low-priced stocks are often subject to price volatility driven by retail interest or short squeeze dynamics rather than fundamental developments.

RETO

Reto Eco-solutions IncBasic Materials

$0.11+$0.02

+22.9%

NASDAQ · Mkt cap $13 M

ReTo announced a 20-to-1 share consolidation approved by its board on September 29, which likely triggered the 22.88% single-day jump as consolidation announcements often create short-term trading activity and technical repricing.

The company announced a twenty-to-one share combination of its Class A shares on September 29, 2026. Share consolidations typically cause immediate price adjustments as the market reprices the stock to reflect the reduced share count while maintaining similar market capitalization. At $0.11 per share, ReTo is a micro-cap stock where consolidation announcements can generate retail trading interest and technical rebalancing. The announcement itself does not provide information about underlying business fundamentals, profitability, or strategic direction, so the move likely reflects mechanical repricing and speculative positioning rather than improved operational prospects. Without knowing the full details of the consolidation ratio's impact or any accompanying business commentary, the jump appears primarily driven by the consolidation event itself rather than new operational or financial developments.

OSRH

Bellevue Life Sciences Acquisition Corp.Healthcare

$0.27+$0.05

+22.7%

NASDAQ · Mkt cap $21 M

No news headlines were found in the last 48 hours, so the 22.73% gain likely reflects either a technical rebound, a rumor or social media catalyst, or a delayed market reaction to an earlier event not captured by the feeds checked.

Bellevue Life Sciences Acquisition Corp. is a SPAC (special purpose acquisition company), a structure that typically trades based on merger prospects, timeline announcements, or sponsor activity rather than operational earnings. The absence of any news in the Yahoo Finance RSS feed in the last 48 hours means this move cannot be attributed to a press release, regulatory filing, or formal announcement by the company itself. For a stock trading at $0.27 with relatively low liquidity, a 22.73% one-day gain is plausible from a modest dollar volume shift. Possible explanations include technical bouncing off support levels, retail social media chatter about the SPAC or its prospective target, a delayed market reaction to news from earlier in the week not reflected in the 48-hour window, or rumors about an imminent merger announcement or deal timeline. Without a headline anchor, attribution is speculative.

CHGA

Change Agents CorporationReal Estate

$2.40+$0.44

+22.4%

NASDAQ · Mkt cap $3.5 M

No news headlines were found in the last 48 hours for CHGA, so the 22.45% gain on September 30 cannot be directly attributed to a reported event. The move likely reflects either a delayed market reaction to older news, technical trading, or undisclosed company developments.

The absence of recent news coverage within the 48-hour window makes it difficult to pinpoint a specific catalyst for the gain. The stock climbed 22.45% to rank among the day's top gainers, a significant move that typically requires an identifiable trigger such as earnings, guidance changes, strategic announcements, or sector-wide momentum. Given that CHGA appears to be a smaller-cap NASDAQ stock (trading at $2.40), it may be more susceptible to technical factors, retail trading activity, or momentum-driven moves that attract less institutional news coverage. Alternatively, the move could reflect a market reaction to news released before the 48-hour snapshot window, or rumors circulating in less mainstream channels. Without headline evidence, we can only categorize the probable cause type rather than confirm it.

ZBAO

Zhibao Technology Inc.Financial Services

$0.10+$0.02

+21.6%

NASDAQ · Mkt cap $6.3 M

Zhibao Technology announced preliminary fiscal 2026 guidance showing strong top-line revenue growth of 10-20%, which likely catalyzed the 21.65% single-day rally in this ultra-low-priced stock.

The company issued preliminary guidance for the fiscal year ended June 30, 2026, highlighting expected revenue growth in the 10-20% range. For a micro-cap stock trading at $0.10, positive forward guidance—especially one framed as "strong"—can trigger significant percentage moves, particularly if the market had been pricing in stagnation or decline. The headline is truncated and does not provide full context on margins, earnings expectations, or comparative prior-year performance, so we cannot assess whether this guidance truly represents a material beat or merely met low expectations. Nonetheless, the timing of the guidance release coinciding with a 21.65% jump suggests investors responded positively to the growth outlook.

LPA

Logistic Properties of the Americas Ordinary Shares

$2.87+$0.58

+20.6%

SES

Synthesis Energy Systems IncConsumer Cyclical

$0.65+$0.11

+20.0%

NYSE · Mkt cap $197 M

No headlines were found in the last 48 hours, so the 20% gain cannot be attributed to any identified news event. The move was likely driven by technical factors, low liquidity amplification, or undisclosed developments.

SES experienced a significant one-day gain of 20.04%, placing it among the top gainers on September 30, 2026, yet no corresponding news headlines appear in the 48-hour window provided. This disconnect suggests the move was not triggered by a major announced event such as earnings, partnerships, or regulatory action. For a micro-cap or penny stock like SES trading at $0.65, price swings of this magnitude can occur from several sources: technical bounces after a downtrend, short covering in a thinly traded security, retail trading activity or social media attention, or potential news that has not yet been indexed by major financial RSS feeds. Without substantive information about the company's current business operations, capital structure, or market dynamics, pinpointing the specific catalyst remains speculative.

EDSA

Edesa Biotech IncHealthcare

$4.27+$0.68

+18.9%

NASDAQ · Mkt cap $55 M

No news headlines from the last 48 hours explain the 18.94% gain in EDSA. The jump likely reflects a clinical trial update, FDA decision, partnership announcement, or technical momentum, but the specific catalyst is unknown from available sources.

EDSA Biotech is a small-cap biotech stock with no reported news in the 48-hour window preceding this 18.94% jump. For biotech stocks of this profile, significant single-day moves typically stem from clinical trial results, regulatory decisions (FDA breakthrough designations or approvals), partnership or licensing announcements, or financing news. The absence of Yahoo Finance headlines does not rule out a real catalyst; news may have broken on company-specific channels, specialized biotech databases, or after the RSS feed snapshot. Alternatively, the move could reflect technical buying pressure or options-related momentum. Without confirmed headline evidence, we cannot determine the specific driver.

AEHL

Antelope Enterprise Holdings LimitedIndustrials

$10.19+$1.62

+18.9%

NASDAQ · Mkt cap $6.5 M

No news headlines were found in the last 48 hours for AEHL, so the 18.9% gain on September 30 likely reflects technical factors, delayed news absorption, or market rumors that have not yet been reported in major financial outlets.

The absence of recent news is notable for a stock that ranked among the top 25 gainers of the day. While strong single-day moves can occasionally follow earnings surprises, major contract wins, or strategic announcements, none of these appear in the available headline data. For a smaller-cap security like Antelope Enterprise Holdings, moves of this magnitude without immediate news coverage may reflect several possibilities. First, material news could have been released through a press release or SEC filing not yet picked up by the RSS feed. Second, the move could be driven by technical factors such as short covering, options-related hedging, or algorithmic trading. Third, market-moving information could have circulated through social media or trading forums ahead of formal news dissemination. Without access to recent filings or confirmed news, the specific catalyst remains unclear, though the timing and magnitude suggest something material occurred or became known to the market during this session.

SOTK

Sono-Tek Corp.

$5.93+$0.94

+18.8%

ADBT

Advasa Holdings, Inc.

$0.12+$0.02

+18.8%

XRPN

Armada Acquisition Corp. II

$16.39+$2.64

+18.7%

LTCH

Latch, Inc.Technology

$0.19+$0.03

+18.3%

NASDAQ · Mkt cap $31 M

No news headlines were found in the last 48 hours, so the 18.31% gain likely reflects technical trading, a delayed market reaction to earlier news, or investor sentiment shift in a highly volatile micro-cap stock.

Latch is a micro-cap security trading at $0.19, and at this price point and market cap, stocks often experience outsized percentage swings on modest absolute dollar volume with minimal fundamental catalyst. The absence of any news in the Yahoo Finance RSS feed over the last 48 hours suggests the move was not triggered by a company announcement, earnings release, or major news event. For a stock at this valuation level, price action can be driven by technical factors such as short covering, algorithmic trading, retail accumulation, or spillover sentiment from related sectors like access technology or smart home. Without access to order flow, insider transactions, or social media sentiment data, we cannot pinpoint a specific trigger. The move ranks 29th among daily gainers, which is notable but not exceptional, consistent with a modest technical bounce in a thinly-traded name rather than a major catalyst event.

DMRC

Digimarc CorpTechnology

$5.86+$0.90

+18.1%

NASDAQ · Mkt cap $169 M

Digimarc announced a registered direct offering of common stock on September 30, 2026, which typically dilutes existing shareholders but may have signaled confidence or upcoming capital deployment that markets rewarded with an 18% gain today.

The headline confirms a registered direct offering announcement on the date of the price jump, which is the only news event provided. Registered direct offerings can trigger mixed reactions: they signal dilution risk to existing shareholders, but they also provide capital that management may deploy for operations, acquisitions, or debt reduction. The +18% gain on the day of announcement is counterintuitive if interpreted as pure dilution worry, suggesting either the market views the capital raise as strategically positive, expected the offering at a favorable price, or responded to unrelated bullish technicals or sector momentum. Without details on offer size, pricing, use of proceeds, or whether this came alongside positive operational news, the causal mechanism remains partially opaque. The timing and magnitude of the gain suggest either strong conviction about the capital deployment ahead or a reaction to something beyond the bare offering announcement itself.

RPGL

Republic Power Group LimitedTechnology

$16.45+$2.26

+17.7%

NASDAQ · Mkt cap $2.6 M

No headlines were reported in the last 48 hours, so the cause of the 17.73% gain cannot be determined from news sources. The move likely reflects either delayed news disclosure, technical trading, or an undisclosed corporate event.

Republic Power Group Limited rallied sharply on September 30th with zero attributed news coverage in the Yahoo Finance feed over the preceding two days. This disconnect between a top-31 daily gainer and media silence creates ambiguity about causation. For a power and utility-focused company, typical catalysts include earnings beats, guidance raises, contract wins, regulatory approvals, or M&A activity. Without headlines, the move could reflect several scenarios: a press release issued after market close on the 29th that hasn't yet propagated to major feeds, institutional accumulation based on non-public information later disclosed, short-covering in a thinly traded name, or technical momentum from support breaks. The 17.73% move is substantial enough to warrant investigation beyond the 48-hour window provided.

CTAAR

ClearThink 1 Acquisition Corp. Rights

$0.21+$0.03

+17.7%

MWYN

Marwynn Holdings, Inc. Common stockConsumer Cyclical

$1.16+$0.17

+17.2%

NASDAQ · Mkt cap $21 M

No news headlines were found in the last 48 hours, so the 17.17% gain cannot be directly attributed to a disclosed event. The move may reflect delayed reaction to a prior announcement, technical trading, or untracked developments.

The absence of recent headlines means no specific catalyst such as earnings, regulatory approval, partnership, or guidance change can be identified from the provided sources. Marwynn Holdings is a thinly traded micro-cap stock trading near $1.16, which characterizes securities prone to sharp moves on modest volume, sentiment shifts, or off-exchange news circulation. The 17.17% single-day gain could reflect short covering, retail accumulation following a prior week's negative pressure, options-driven gamma moves, or announcement made through channels not captured by the Yahoo Finance RSS feed used here. Without additional context, attribution remains speculative.

MNKD

MannKind CorpHealthcare

$3.91+$0.57

+16.9%

NASDAQ · Mkt cap $1.3 B

No news was reported in the last 48 hours, so the 16.92% gain cannot be attributed to a specific headline catalyst; the move may reflect technical trading, market sentiment shifts, or delayed information absorption by the market.

MannKind Corporation is a small-cap biopharmaceutical company focused on inhalable drug delivery, which historically has been volatile and responsive to clinical trial results, regulatory developments, and financing announcements rather than day-to-day fundamentals. The absence of recent news headlines in the 48-hour window suggests the catalyst, if news-driven at all, either occurred earlier and is now being repriced into the stock, circulated via sources not captured by the RSS feed, or is based on market technicals and sentiment rather than disclosed information. For a stock of this type, common catalysts include positive Phase trial data, partnerships, or institutional accumulation ahead of announcements, but none of these can be confirmed from the provided evidence. The magnitude of the single-day gain (16.92%, ranking 34th of daily gainers) is material enough to suggest a meaningful event rather than random drift, but without headline support, the specific cause remains unclear.

BACCR

Blue Acquisition Corp. Right

$0.49+$0.07

+16.6%

NASDAQ

No news headlines were found in the last 48 hours for BACCR, so the 16.64% gain likely reflects either a technical or structural factor specific to this blank-check company's rights offering mechanics, or an undetected announcement.

Blue Acquisition Corp. Right (BACCR) is a SPAC rights component, which means its price behavior can be driven by factors distinct from traditional equities. With no news identified in the provided headlines, the gain could reflect several possibilities worth considering. First, rights offerings sometimes experience sharp moves when underlying SPAC units trade up due to M&A rumors, deal progress announcements, or redemption dynamics that are not immediately captured in broad news feeds. Second, low-float, low-price securities like SPAC rights can experience technical rallies driven by short covering, options activity, or algorithmic trading. Third, the stock may have reacted to a delayed or platform-specific disclosure not yet aggregated into Yahoo Finance's RSS feed. Without seeing the actual catalyst, any explanation remains speculative rather than grounded in confirmed events.

BESS.WT

$1.29+$0.18

+16.2%

MSGY

Masonglory LimitedIndustrials

$5.65+$0.80

+16.0%

NASDAQ · Mkt cap $5.8 M

Masonglory announced a US$1.0 million private placement to fund continued acquisition of equity interests in a German company, which likely drove investor optimism about growth prospects and fueled the 16% single-day rally.

On September 28, Masonglory Limited announced a US$1.0 million private placement structured to finance ongoing acquisition of equity stakes in Beta Beteiligungs und Besitz GmbH. The company is a Hong Kong-based subcontractor in wet trades and ancillary services. Capital raises tied to M&A activity often signal management confidence in growth opportunities and can attract buying if investors view the target as strategically valuable. The headline confirms the funding mechanism and purpose but does not disclose deal valuation, acquisition timeline, target profitability, or financial terms of the placement itself. The 16% gain suggests the market reacted positively to the expansion signal, though without more detail on the acquisition rationale or Beta's business profile, the magnitude of enthusiasm relative to the actual strategic merit remains unclear.

PMVP

PMV Pharmaceuticals, Inc.

$1.67+$0.23

+16.0%

TLSA

Tiziana Life Sciences PLC

$1.11+$0.15

+15.9%

NUCLW

Eagle Nuclear Energy Corp. Warrants

$0.64+$0.09

+15.5%

GENVR

Gen Digital Inc. Contingent Value Rights

$0.87+$0.11

+15.0%

NASDAQ

GENVR rose 14.97% on positive sentiment from CEO commentary on raised fiscal 2027 guidance and an AI agent product announcement, following a technical oversold condition after a 32.7% four-week decline.

The stock appears to have benefited from multiple converging factors. On September 28, CEO Vincent Pilette addressed acquisition speculation while highlighting raised fiscal 2027 outlook, which drove a 5% after-hours rally. On September 30, Gen Digital announced Engine, an AI agent platform for insurance shopping, positioning the company in the growing AI commercialization space. Separately, technical analysis noted the stock had fallen into oversold territory and Wall Street analysts were revising earnings estimates upward. For a contingent value rights (CVR) instrument, which is a claim on a portion of future proceeds, the combination of improved forward guidance, positive product innovation, and technical mean-reversion after heavy selling likely triggered the jump. CVRs are particularly sensitive to changes in perceived exit value or parent company performance.

QSI

Quantum-Si incorporated

$1.07+$0.14

+14.8%

CVM

CEL-SCI CorpHealthcare

$2.04+$0.26

+14.5%

LMFA

LM Funding America IncFinancial Services

$1.13+$0.14

+14.5%

NASDAQ · Mkt cap $1.5 M

No news was reported in the last 48 hours, so the 14.49% jump in LMFA stock likely reflects a technical rebound, delayed market reaction to older information, or untracked developments outside major news feeds.

The absence of any headlines in the last 48 hours means no earnings announcement, regulatory decision, merger activity, or guidance change can be identified as the direct catalyst. LMFA is a small-cap lending and funding company with typically lower liquidity, making it susceptible to outsized percentage moves on relatively modest volume. The stock could have rebounded after prior weakness, responded to a delayed SEC filing or investor presentation not yet reflected in major news aggregators, or moved on technical or short-covering factors. Small-cap stocks in the lending space can also be sensitive to broader credit market sentiment shifts or rumors that don't immediately appear in official news sources. Without corroborating headlines, the specific driver remains unclear.

CLRO

ClearOne IncTechnology

$5.37+$0.68

+14.4%

NASDAQ · Mkt cap $13 M

No news headlines were found in the last 48 hours, so the 14.39% gain cannot be attributed to a specific announced event. The move may reflect technical trading, delayed news, or market sentiment shifts affecting ClearOne specifically.

ClearOne Inc is a provider of unified communications and collaboration solutions. The absence of news in the RSS feed over the last 48 hours means we cannot point to earnings, product announcements, partnerships, or other corporate developments as the direct cause of today's 14.39% jump. This stock could be responding to several categories of catalyst: short covering or technical momentum if it had been oversold, sector-wide strength in collaboration technology, insider buying or analyst upgrades not yet reflected in public headlines, or general speculative positioning. Without access to intraday volume patterns, short interest data, or delayed news sources, we cannot definitively separate genuine company news from technical or sentiment-driven movement.

PWCM

PowerCompute, Inc.Financial Services

$1.13+$0.14

+14.4%

NASDAQ · Mkt cap $1.5 M

No news headlines were found in the last 48 hours for PWCM, so the 14.36% gain cannot be attributed to a specific announced catalyst. The move likely stems from technical trading, market sentiment, or unindexed developments.

The absence of recent news is notable given the stock's +14.36% single-day gain and its ranking as the 46th biggest gainer on NASDAQ. For a micro-cap or low-priced stock like PWCM at $1.13, price moves of this magnitude can occur from several non-news sources: retail trading momentum, short covering, options-related hedging flows, or sector rotation into whatever vertical PowerCompute operates in. Without headline visibility, it is reasonable to infer the move may reflect either a delayed market reaction to an older announcement, insider activity not yet reflected in major news feeds, or pure technical/sentiment-driven trading. The complete absence of indexed news coverage within 48 hours suggests either low analyst attention or that any catalyst remains below the threshold of major financial news aggregation.

USDEW

StablecoinX Inc. Warrants

$5.17+$0.65

+14.3%

FBDT

First Breach Inc.

$1.05+$0.13

+14.2%

XOS

Xos, Inc.Industrials

$3.19+$0.40

+14.1%

NASDAQ · Mkt cap $41 M

No news headlines were published in the last 48 hours, so the 14.13% gain cannot be attributed to a specific announced event. The move is likely driven by technical factors, delayed market reactions, or untracked rumors.

XOS shares jumped 14.13% on September 30, 2026, but no news appeared in the Yahoo Finance RSS feed within the prior 48 hours. This disconnect means the catalyst remains unknown from the provided evidence. Xos is an electric vehicle manufacturer historically subject to volatility from sector sentiment shifts, capital raises, production updates, or short-covering rallies that may not immediately surface in major headline feeds. Without visibility into company filings, social media discussion, or alternative news sources, the specific trigger cannot be identified. The move could reflect a delayed market reaction to an earlier announcement, technical bounce from oversold conditions, or an event not yet captured by the news aggregator.

MDXH

MDxHealth SAHealthcare

$0.59+$0.07

+13.1%

NASDAQ · Mkt cap $39 M

No news headlines were found in the last 48 hours to explain MDXH's 13.06% gain, so the driver remains unclear; the jump could reflect a delayed announcement, technical rebound, or sector rotation in small-cap biotech stocks.

MDxHealth is a molecular diagnostics company, and a 13% single-day move on no apparent fresh news is typical of low-liquidity, small-cap healthcare stocks where trading can be volatile and reactive to stale or rumored information. The absence of any headlines in the Yahoo Finance RSS feed in the 48 hours prior to this snapshot makes it impossible to identify a specific catalyst. Possible explanations, offered as inference rather than fact, include a delayed or embargoed clinical trial result, short covering, a broker upgrade not yet widely indexed, sector rotation into neglected diagnostic plays, or pure technical momentum off prior lows. Without evidence of a concrete news event, earnings beat, regulatory approval, or partnership announcement, attributing causation would be speculative.

Biggest Losers

Wed, Sep 30, 2026 50

SHOT

Safety Shot IncFinancial Services

$1.98−$7.88

-79.9%

NASDAQ · Mkt cap $1.7 B

Safety Shot Inc crashed nearly 80% on September 30 with no news headlines available in the last 48 hours, suggesting the catalyst may be an undisclosed announcement, regulatory action, or significant operational event that has not yet been widely reported.

The complete absence of recent news headlines combined with an extreme single-day loss of nearly 80 percent makes it difficult to pinpoint the exact cause from the available evidence. For a small-cap stock like Safety Shot Inc, this magnitude of decline typically stems from a few categories of events: a significant earnings miss or warning, regulatory setback or product recall, insider selling revelation, failed capital raise or dilutive financing announcement, or material litigation news. The fact that no headlines appear in the 48-hour window does not rule out that news broke before that period or that the market is reacting to an overnight development not yet picked up by major financial news aggregators. Without confirmed reporting, any specific explanation would be speculation.

LQDA

iShares USD Corp Bond UCITS ETFHealthcare

$30.19−$40.52

-57.3%

NASDAQ · Mkt cap $6.1 B

A U.S. District Court ruled that Liquidia infringed two patent claims held by United Therapeutics related to Liquidia's drug Yutrepia, triggering a 57% collapse in the stock. However, there is a critical mismatch: LQDA is a bond ETF, not Liquidia Corp stock, suggesting the news headlines may be m…

The headlines consistently describe a patent infringement ruling against Liquidia Corp, a biotech company, with its Yutrepia drug infringing United Therapeutics patents. The ruling on two of six asserted claims poses significant commercial risk to Liquidia's flagship product. However, LQDA is listed as an iShares USD Corporate Bond ETF, a fixed-income fund with no direct connection to Liquidia Corp's patent dispute. A 57% single-day drop in a diversified corporate bond ETF cannot be explained by litigation against one biotech company. Either the ticker symbol is misidentified and these headlines refer to Liquidia Corp stock (ticker LQDA may be incorrect), or the headline feed is mislabeled. Without clarification on whether LQDA actually tracks corporate bonds or is somehow heavily concentrated in Liquidia Corp, the true cause remains unclear.

COPL.WT

Copley Acquisition Corp WT

$0.02−$0.02

-47.5%

DKI

DARKIRIS INCCommunication Services

$1.57−$1.05

-40.3%

NASDAQ · Mkt cap $8.5 M

DarkIris announced expansion plans for its Cine3.AI platform and a U.S. subsidiary on September 30, but the market punished the stock with a 40% decline, suggesting investors may have been disappointed by the announcement's substance, lacked confidence in execution, or reacted to undisclosed deta…

The two headlines released on September 30 describe DarkIris advancing its Cine3.AI global rollout and establishing a North American subsidiary, which appear to be positive strategic announcements. However, the 40% single-day crash contradicts the constructive tone of these press releases. This suggests the market either found the business update insufficient in detail or confidence, perceived the expansion plans as dilutive or risky given the company's financial position, or the headlines omit negative information contained in the full announcement (such as revised guidance, funding needs, or competitive challenges). Without access to the complete investor update or management commentary, the precise trigger remains unclear, but the magnitude of the decline indicates serious investor skepticism about the path forward.

AMPGZ

Amplitech Group, Inc. Series B Right

$0.11−$0.06

-36.6%

NASDAQ

No news headlines were found in the last 48 hours to explain the 36.6% drop in this Series B right offering, so the cause remains unknown; the move may reflect overall market conditions, expiration dynamics, or delayed reporting of company-specific events.

The absence of any recent news headlines makes it impossible to pinpoint a specific catalyst for today's sharp decline. AMPGZ is a Series B rights offering, a derivative security whose value depends on the underlying company's stock price and the terms of the rights. Rights offerings are sensitive to changes in the underlying stock, interest rates, and expiration proximity. The 36.6% single-day drop could reflect a significant decline in Amplitech's common stock, a deterioration in the value of exercising the rights, market-wide volatility, or a loss of liquidity as the rights approach or pass their expiration date. Without headlines or recent company announcements in the data provided, it is not possible to determine whether this was driven by Amplitech-specific news, sector dynamics, or purely technical factors in the rights security itself.

RFL

Rafael Holdings IncReal Estate

$1.34−$0.72

-34.9%

NYSE · Mkt cap $94 M

Rafael Holdings' stock collapsed 34.88% after the company announced that its Phase 3 trial of Trappsol Cyclo for Niemann-Pick Disease Type C failed to meet its primary statistical endpoint, despite showing a directionally favorable treatment effect.

The evidence is clear and direct. Rafael announced topline results from the pivotal Phase 3 TransportNPC study showing that Trappsol Cyclo did not achieve statistical significance on its primary endpoint, the 4-domain NPC Clinical Severity Scale. While the drug demonstrated a directionally favorable effect versus placebo, the failure to meet statistical significance on a primary endpoint in a Phase 3 trial is a major clinical and commercial setback for a biotech company. This likely represents the loss of a key revenue driver and eliminates a near-term regulatory approval catalyst. The market repriced the stock sharply on this news, with premarket trading showing a 25% drop that widened further by close. For a development-stage biotech, a failed pivotal trial typically triggers significant re-valuation downward.

CVRX

CVRx, Inc.Healthcare

$1.73−$0.91

-34.5%

NASDAQ · Mkt cap $75 M

CVRx announced late-breaking clinical data on Barostim at the HFSA meeting on September 29, but the stock fell 34.47% the next day, suggesting the market viewed the data as disappointing or insufficient to justify current valuation despite the company's positive framing.

CVRx announced what it characterized as late-breaking data and new clinical evidence for Barostim at the Heart Failure Society of America's annual meeting on September 29. The headline itself is vague and does not disclose the specific results, efficacy metrics, or any regulatory or commercial implications. The 34% one-day drop the following day indicates the market's reaction was sharply negative. This could mean the actual data presented fell short of investor expectations, showed less favorable efficacy or safety outcomes than anticipated, failed to show statistical significance, or contained guidance that management was unable to immediately commercialize or scale the product as hoped. Alternatively, the market may have been pricing in more bullish results before the announcement. Without the actual clinical results, we cannot determine whether the data was genuinely weak or whether expectations were simply misaligned with reality.

OYSER

Oyster Enterprises II Acquisition Corp Rights

$0.08−$0.04

-33.3%

SKYH.WT

Sky Harbour Group Corporation

$0.13−$0.06

-32.1%

COLA

Columbus Acquisition Corp Ordinary Shares

$7.30−$3.16

-30.2%

NEXR

Nexera Technologies Ltd.Consumer Cyclical

$1.29−$0.49

-27.5%

SVRN

OceanPal Inc.Industrials

$49.00−$18.58

-27.5%

NASDAQ · Mkt cap $13 M

OceanPal Inc. dropped 27.49% on September 30, 2026, but no news headlines from the past 48 hours are available to explain the move, making the specific catalyst unknown.

The absence of recent news headlines makes it impossible to attribute this sharp 27.49% decline to a specific announced event such as earnings, contract loss, regulatory action, or guidance revision. OceanPal Inc. operates in the shipping and maritime sector, which is sensitive to multiple potential triggers including commodity price movements, freight rate changes, vessel utilization reports, geopolitical disruptions affecting trade routes, fuel costs, or company-specific operational announcements that may not yet have propagated to major news feeds. The magnitude of the decline suggests a material negative catalyst rather than routine volatility, but without access to company filings, press releases, or market commentary from the relevant trading day, the underlying cause remains speculative. Possible categories include an unannounced earnings miss, casualty loss, contract cancellation, or macroeconomic headwinds affecting shipping demand, though these are inferences rather than facts.

CPOP

Pop Culture Group Co., LtdCommunication Services

$3.31−$1.11

-25.1%

NASDAQ · Mkt cap $4.8 M

CPOP fell 25% with no news disclosed in the last 48 hours, suggesting the driver is either a delayed announcement, earnings miss, or broader market pressure that has not yet been reported in available headlines.

The absence of any news headlines in the 48 hours preceding this 25% drop creates significant ambiguity. A single-day loss of this magnitude in a small-cap stock typically corresponds to a specific catalyst: earnings disappointment, guidance reduction, insider selling, regulatory action, or significant industry headwinds. Pop Culture Group operates in entertainment and media licensing, sectors sensitive to content performance and consumer demand shifts. Without access to the news that triggered the move, the most likely categories are either a late-afternoon or pre-market earnings or guidance announcement not yet captured in the RSS feed lag, deterioration in quarterly financial metrics, or market-wide tech or entertainment sector rotation. The timing gap between the price action and news availability makes causation unclear from the evidence at hand.

OXBR

Oxbridge Re Holdings LtdFinancial Services

$0.98−$0.30

-23.1%

NASDAQ · Mkt cap $11 M

No news headlines were found in the last 48 hours, so the 23% decline cannot be directly attributed to a specific announced event. The drop likely stems from technical selling, market-wide pressure, or undisclosed company developments.

Oxbridge Re Holdings is a small-cap reinsurance company trading at $0.98 with a steep single-day loss of 23%, ranking it among the day's largest percentage decliners. However, no news appeared on Yahoo Finance in the preceding 48 hours to explain the move. This absence of reported headlines does not rule out causation—the company may have issued a press release, disclosed information via SEC filing, or faced negative sentiment that took time to propagate to major news feeds. For a micro-cap reinsurance firm, typical catalysts include catastrophic event losses, premium shortfalls, capital raises, regulatory actions, or downgrades by analysts. Without access to company filings or insider communications, attributing the move requires inference. The magnitude of the decline suggests either a material operational or financial announcement, or broad sector pressure affecting reinsurance stocks on that date.

AIB

AIB Acquisition CorporationTechnology

$1.33−$0.39

-22.3%

NCT

Intercont (Cayman) Limited Ordinary sharesIndustrials

$1.62−$0.44

-22.0%

NASDAQ · Mkt cap $38 M

No news headlines were found in the last 48 hours, so the 22% drop cannot be traced to a specific public announcement or event reported by Yahoo Finance. The move likely reflects either delayed market reaction to untracked news, technical selling, or sector/market headwinds.

The absence of recent headlines makes attribution difficult. NCT is a Cayman Islands-incorporated ordinary share, which suggests it may be a holding company or financial instrument with limited public information flow. A 22% single-day decline of this magnitude typically correlates with material corporate news—earnings misses, guidance cuts, regulatory actions, or liquidity events—but none are documented in the search results provided. It's possible the catalyst broke outside the Yahoo Finance RSS feed timeline, occurred via regulatory filing rather than press release, reflects institutional redemptions or fund rebalancing, or stems from broader sector rotation or market stress. Without additional data on NCT's fundamentals, recent filings, or analyst activity, the specific trigger remains unknown.

JAGU

Jaguar Uranium Corp.

$1.11−$0.29

-20.7%

KUST

Kustom Entertainment IncCommunication Services

$0.42−$0.11

-20.1%

NASDAQ · Mkt cap $1.8 M

Kustom Entertainment announced a 1-for-10 reverse stock split on September 29, which typically signals financial distress and triggers immediate selling pressure as investors react negatively to the dilutive capital restructuring.

The company announced a reverse stock split on September 29, 2026, effective the same day. Reverse splits are generally perceived as negative signals by the market because they are typically implemented by companies facing financial difficulties, low trading volume, or exchange compliance issues (NASDAQ listing requirements). While a reverse split mechanically adjusts share count upward in price per share, the market reaction is usually swift and negative because it does not improve underlying fundamentals. The 20% single-day decline on the announcement date suggests investors interpreted the reverse split as confirmation of operational or financial stress. Without additional context on the company's financial condition, compliance status, or strategic rationale beyond the bare announcement, the sell-off appears to be a standard market response to reverse split announcements in the penny-stock and microcap space.

KFIIR

K&F Growth Acquisition Corp. II Rights

$0.08−$0.02

-20.0%

NASDAQ

No news headlines were found in the last 48 hours to explain the 20% drop in KFIIR, a SPAC rights offering. The decline likely reflects either technical selling pressure in a low-volume, low-priced security or deterioration in market sentiment around the underlying acquisition target.

KFIIR is a rights unit tied to K&F Growth Acquisition Corp. II, a special-purpose acquisition company. Rights offerings are inherently volatile and illiquid securities that trade on thin volume and often experience sharp intraday swings disconnected from traditional fundamentals. Without recent news headlines, the 20% decline could stem from several typical catalysts for this security class: reduced conviction around the pending merger or business combination target, broader SPAC market weakness, technical selling by arbitrageurs or speculators, or an adverse update about the sponsor or acquisition timeline that has not yet appeared in major news feeds. Rights trade on speculation and sentiment rather than cash flows, making them particularly susceptible to momentum-driven selloffs.

SCTX

Scribe Therapeutics Inc.Healthcare

$18.41−$4.60

-20.0%

NASDAQ · Mkt cap $586 M

Scribe Therapeutics dropped nearly 20 percent on September 30, but the only recent headline provided is unrelated to SCTX and mentions Cathie Wood's trades in two other stocks, leaving the cause of this sharp decline unclear from available news.

The headline about Cathie Wood's $64 million bet on two stocks does not name SCTX and therefore does not explain the stock's decline. Without specific news tied to Scribe Therapeutics, the 19.98 percent drop could stem from several categories: a clinical trial setback or safety concern in gene-editing therapeutics, a guidance reduction or capital raise announcement, competitive developments in the CRISPR space, broader biotech sector weakness, or technical/algorithmic selling. Early-stage biotech firms like SCTX are sensitive to regulatory announcements, cash burn concerns, and clinical trial results. Without access to earnings calls, FDA actions, or company statements released in the past 48 hours, we cannot pinpoint the specific trigger.

INDP

Indaptus Therapeutics, Inc.Healthcare

$2.30−$0.57

-19.8%

NASDAQ · Mkt cap $125 M

No news headlines were found in the last 48 hours, so the 19.76% drop cannot be directly attributed to a disclosed event; the decline likely reflects broader market pressure, a delayed news release, or investor reaction to clinical or business developments not yet captured in the headline feed.

Indaptus Therapeutics is a clinical-stage biotech company, and such stocks are highly sensitive to development updates, trial results, financing announcements, and regulatory news. The absence of any headlines in the last 48 hours despite a significant one-day loss suggests either that the catalyst occurred but was not yet indexed by Yahoo Finance's RSS feed, or that the move was driven by intraday rumors, sector rotation, or technical selling unrelated to company-specific news. Biotech stocks of this profile commonly move sharply on trial data readouts, capital raises, partnership announcements, or guidance shifts, any of which could explain a 20% single-day decline. Without the headline, however, we cannot confirm which category applied.

GIFT

RDE, Inc.

$0.49−$0.12

-19.7%

SZZLR

Sizzle Acquisition Corp. II

$0.10−$0.03

-19.6%

NASDAQ

No news headlines were published in the last 48 hours, so the 19.62% decline cannot be attributed to a specific disclosed event. The drop likely stems from general SPAC deterioration, illiquidity, or technical selling pressure.

Sizzle Acquisition Corp. II is a blank-check acquisition company with a very low stock price of $0.10, which typically indicates an inactive or failed SPAC merger process. No recent news was available to explain the intraday loss. SPACs in this condition commonly experience price declines due to several structural factors: expiration of merger deadlines, shareholder redemption pressure, loss of investor confidence in deal completion, or simple illiquidity that can amplify price swings on modest trading volume. Given the lack of any disclosed catalyst, the move is most likely technical or driven by internal SPAC dynamics rather than external company news. The extremely low price point also makes the stock vulnerable to larger percentage swings on smaller absolute dollar moves.

PYXS

Pyxis Oncology, Inc.Healthcare

$2.33−$0.57

-19.6%

NASDAQ · Mkt cap $214 M

Pyxis Oncology announced a $282.6 million public offering of common stock and warrants on September 29-30, causing a 19.55% single-day drop as shareholder dilution concerns triggered selling pressure.

The timeline and magnitude of the decline directly correlate with the company's announcement of a registered public offering. On September 29, the company announced the proposed offering, triggering a 3.5% after-hours decline. On September 30, the company announced the pricing of up to $282.6 million in common stock and warrants, and the stock fell 19.55% during the regular session. This pattern is typical for clinical-stage biotech companies announcing equity raises, as existing shareholders face immediate dilution risk. The size of the offering relative to the company's apparent market capitalization appears material enough to warrant the sharp reaction. No competing catalysts are evident in the provided headlines, and the temporal alignment between announcement and price action is direct and unambiguous.

BSEM

BioStem Technologies, Inc.Healthcare

$3.16−$0.75

-19.2%

NASDAQ · Mkt cap $60 M

BioStem announced a $3 million at-the-market private placement on September 30, which likely triggered shareholder dilution concerns and selling pressure, driving the 19% intraday decline.

The company announced a private placement priced at-the-market under Nasdaq rules on the same day as the price drop. At-the-market offerings typically involve issuance of new shares at prevailing market prices, which creates immediate dilution to existing shareholders. The timing and magnitude of the decline suggest market participants reacted negatively to the announcement, possibly due to concerns about the dilutive impact on ownership stakes or questions about why the company needed capital at this point. The $3 million raise is relatively modest for a Nasdaq-listed company, which may signal financial stress or opportunistic timing. Without details on use of proceeds, debt levels, or burn rate, the full context remains unclear, but equity dilution anxiety is the most direct link between the news and the stock action observed.

ONEN

Hennessy Capital Investment Corp. VII

$2.14−$0.49

-18.6%

CCG

Cheche Group Inc. - Class A Ordinary SharesCommunication Services

$6.19−$1.37

-18.1%

NASDAQ · Mkt cap $34 M

No news headlines were found in the last 48 hours, so the 18.12% decline likely stems from a delayed announcement, technical selling, broad market weakness, or company-specific rumor not yet captured in the provided news feed.

The absence of any recent news headlines in the Yahoo Finance RSS feed makes it impossible to identify a specific catalyst for the sharp 18.12% drop in CCG. This magnitude of single-day decline in a NASDAQ-listed security typically reflects material negative information—earnings disappointment, guidance reduction, insider selling, regulatory setback, or market-wide sector pressure—but without headline confirmation, the cause remains speculative. The move could reflect news released outside the monitored news sources, intraday technical breakdown, or a delayed market reaction to older information. Without knowing the company's sector, valuation metrics, or recent trading patterns, it is not possible to narrow the likely category further than these generic possibilities.

CBRG

Chain Bridge IFinancial Services

$2.69−$0.59

-18.0%

DXST

Decent Holding Inc Ordinary SharesIndustrials

$2.49−$0.55

-18.0%

NASDAQ · Mkt cap $6.0 M

Decent Holding fell 17.96% despite announcing a new AI-powered senior care subscription service through SunCare, suggesting the market viewed the initiative as insufficient to offset existing concerns or valuations.

The company announced on September 29 the launch of an RMB 500-per-month AI-powered in-home senior care subscription through a partnership with Ruilan International, targeting its approximately 200,000 paid-member base under a three-tier framework. While this represents a concrete product expansion and recurring revenue model, the sharp 18% decline on the same day indicates the market either (1) had already priced in this service launch, (2) questions the commercial viability or unit economics of the offering, or (3) was responding to broader concerns about the business that the announcement failed to address. The news itself is substantive but lacks financial metrics, growth projections, or management commentary that might have buoyed sentiment. No earnings report, guidance revision, or material setback was mentioned, making it unclear whether the decline reflects disappointment in execution or external market pressure on the stock.

GLAS

Glass House Brands Inc.

$5.60−$1.17

-17.3%

GRNQ

Greenpro Capital CorpIndustrials

$7.41−$1.51

-16.9%

NASDAQ · Mkt cap $24 M

No news headlines were found in the last 48 hours, so the 16.91% decline in GRNQ cannot be attributed to a specific disclosed event; the drop likely reflects market sentiment, technical selling, or undisclosed news.

The absence of any recent news headlines makes it difficult to pinpoint a concrete catalyst for the 16.91% decline in GRNQ. Greenpro Capital Corp is a small-cap fintech and blockchain-focused company, and stocks in this category are typically sensitive to sector rotation, liquidity concerns, and macroeconomic sentiment shifts. The stock's ranking as the 31st biggest loser suggests it experienced notable selling pressure relative to the broader market. Without headline evidence, the move could reflect technical breakdown following prior resistance, outflows from a sector-wide correction in fintech or cryptocurrency-adjacent names, a delayed market reaction to an earlier announcement, or simple liquidity-driven selling in a lower-float security. Retail or insider activity could also be a factor, though this remains speculative.

MGRT

Mega Fortune Company LimitedTechnology

$100.01−$19.99

-16.7%

NASDAQ · Mkt cap $1.3 B

No news headlines were found in the last 48 hours, so the 16.66% drop likely stems from an undisclosed announcement, market-wide sell-off, technical breakdown, or delayed news not yet indexed by Yahoo Finance.

The absence of recent news headlines makes it impossible to identify a specific catalyst for the 16.66% decline in MGRT on September 30, 2026. Given the magnitude of the drop and the stock's ranking as the 32nd biggest loser, the move appears material rather than routine volatility. Without access to company filings, press releases, or broader market context for that date, several categories of events remain plausible: a negative earnings report or guidance reduction released outside the indexed news window, a sector-wide correction affecting Nasdaq stocks, a technical breakdown triggering algorithmic selling, or a delayed announcement that has not yet propagated to major news feeds. The lack of corroborating headlines limits our ability to distinguish among these possibilities with any confidence.

LNAI

Lunai Bioworks Inc.Healthcare

$1.48−$0.29

-16.4%

NASDAQ · Mkt cap $10 M

No news headlines were found in the last 48 hours to explain LNAI's 16.35% drop, making the specific catalyst unclear.

The absence of any reported news in the past two days leaves the cause of this significant decline unclear from public sources. For a small-cap biotech stock like Lunai Bioworks, typical catalysts for single-day drops of this magnitude include clinical trial results, regulatory setbacks, analyst downgrades, insider selling, sector-wide biotech weakness, or adverse research announcements. The stock's low price of $1.48 and ranking as the 33rd biggest loser suggest either a meaningful negative event occurred but was not yet captured in the news feed provided, or the move was driven by technical factors such as stop-loss triggers, options expiration, or negative sentiment in the broader biotech sector. Without evidence in the headlines, we cannot determine whether this was company-specific or market-driven.

JAGX

Jaguar Health IncHealthcare

$4.50−$0.86

-16.0%

NASDAQ · Mkt cap $4.5 M

Jaguar Health fell 15.97% despite positive news about its crofelemer drug being accepted for presentation at a major gastroenterology conference, suggesting the market may have already priced in the study announcement or investors were disappointed by the preliminary nature of the results.

The company announced that Napo Pharmaceuticals, its subsidiary, had an abstract accepted for presentation at the ACG 2026 conference in October covering preliminary results from a crofelemer study in short bowel syndrome patients. This is typically viewed as a positive development for a clinical-stage biotech company, as conference presentations generate visibility and validate ongoing research. However, the market sold off sharply on the news. The most likely explanations are that investors had already anticipated this announcement before it was released, the word "preliminary" raised concerns about incomplete or underwhelming data, or the results failed to meet internal market expectations despite formal acceptance. Alternatively, the decline may reflect broader market sentiment toward Jaguar Health unrelated to this specific news, such as cash position concerns, capital raise risks, or sector headwinds affecting small-cap biopharmas.

SPEGR

Silver Pegasus Acquisition Corp Rights.

$0.15−$0.03

-15.9%

NASDAQ

No news headlines were found in the last 48 hours, but Silver Pegasus Acquisition Corp Rights experienced a 15.88% drop, likely due to typical SPAC rights volatility, expiration pressure, or loss of merger momentum.

The absence of recent news headlines makes it impossible to identify a specific catalyst for SPEGR's 15.88% decline today. However, this security's structure as a SPAC rights offering provides plausible explanatory categories. Rights offerings are inherently time-decay instruments with expiration dates; as expiration approaches, their value compresses rapidly, particularly if the underlying SPAC has not announced a merger or if investor confidence in deal completion has waned. SPAC rights are also sensitive to redemption dynamics and public shareholder enthusiasm. Without headline confirmation, the move could reflect routine volatility in this illiquid, derivative security class, deteriorating sentiment toward the sponsor's merger prospects, or an expired or expiring deadline. A secondary explanation is delayed market reaction to an older announcement not captured in the 48-hour window shown here.

SEED

Origin Agritech Ltd

$0.78−$0.15

-15.8%

UZX

Linkage Global IncConsumer Cyclical

$1.36−$0.25

-15.5%

NASDAQ · Mkt cap $7.8 M

Linkage Global announced termination of a non-binding letter of intent with Capital Finance Limited, likely disappointing investors expecting a potential strategic transaction or financing arrangement, triggering a 15.53% single-day selloff.

The headline establishes that Linkage Global terminated a non-binding LOI with Capital Finance Limited on September 29, 2026. While the full press release text is truncated, termination of a potential financing or strategic partnership typically signals deal failure or shifting strategic direction, both of which can depress sentiment in small-cap stocks heavily dependent on near-term capital raises or transformative transactions. The timing (announcement after market close on the 29th, stock tanking on the 30th) aligns with direct causality. The company describes itself as AI-enabled wellness infrastructure, a space attracting both speculative interest and volatility. Without details on why the LOI was terminated, whether alternative funding exists, or what the LOI terms were, the precise magnitude of negative impact cannot be quantified, but a 15% drop is consistent with loss of confidence in near-term transaction prospects.

XHLD

TEN Holdings, Inc. Common StockCommunication Services

$0.63−$0.12

-15.4%

NASDAQ · Mkt cap $92 M

No news headlines were available in the last 48 hours to explain the 15.36% drop in XHLD stock, so the cause remains unclear without additional information.

The absence of recent news makes it difficult to pinpoint a specific catalyst for today's 15.36% decline in XHLD. Stocks trading at very low price levels like $0.63 can be sensitive to a range of factors including technical selling, broader market momentum, changes in sentiment toward the sector or company, or delayed disclosure of company-specific developments that may not yet appear in headline aggregators. For a stock ranked as the 38th biggest loser, the move is notable but without corroborating news it is impossible to distinguish between company-driven factors such as guidance reductions or operational challenges versus market-wide or technical factors. The lack of headlines could indicate either that no major news was released or that developments are still spreading through market channels before broader dissemination.

AVXL

Anavex Life Sciences Corp

$2.02−$0.37

-15.3%

KALA

Kala Pharmaceuticals IncHealthcare

$0.43−$0.08

-15.2%

CCEC

Capital Clean Energy Carriers Corp.

$18.32−$3.25

-15.1%

QNC

Quantum eMotion Corp.

$1.48−$0.26

-14.9%

RELI

Reliance Global Group Inc.

$2.28−$0.40

-14.9%

SLXN

Biomotion SciencesHealthcare

$0.27−$0.05

-14.5%

NASDAQ · Mkt cap $540 K

Biomotion Sciences fell 14.51% despite a positive clinical trial announcement on the same day, suggesting the market either discounted the news or responded to warrant dilution and cash-burn concerns typical of early-stage biotech.

The stock posted a significant loss on a day when Silexion announced successful dosing of the first patient in a Phase 2/3 trial for SIL204 in pancreatic cancer, which would normally be viewed as clinical progress. However, the company also announced an exercise of warrants on September 29, which signals dilution to existing shareholders and potential cash-burn pressure. Biotech stocks, especially clinical-stage companies burning cash, often trade on a combination of trial progress and capitalization structure. The warrant exercise may have outweighed investor sentiment on the trial news, or investors may have viewed the announcement as insufficient proof of concept to justify the stock's valuation. Alternatively, the move could reflect broader market rotation away from early-stage biotech or sector-specific headwinds unrelated to company-specific news.

SOAR

Volato Group, Inc.Industrials

$0.34−$0.06

-14.3%

NYSE · Mkt cap $7.8 M

No news headlines were reported in the last 48 hours for Volato Group, so the 14.26% decline cannot be directly attributed to a disclosed event; the move may reflect broader market conditions, technical selling, or undisclosed company developments.

The absence of news in the Yahoo Finance RSS feed over the past two days makes it impossible to tie SOAR's steep decline to a specific catalyst. Volato Group is a fractional aircraft ownership and charter company, a sector that can be sensitive to fuel prices, travel demand signals, and general risk-sentiment shifts in discretionary consumer spending. Without headlines, the drop could stem from several plausible but unconfirmed sources: delayed earnings or guidance disappointment not yet widely reported, technical breakdown through a support level triggering stop-losses, sector-wide weakness in aviation or luxury services, or broader market rotation out of small-cap stocks. Micro-cap stocks trading near $0.34 often experience elevated volatility and can move on sparse information or insider activity not immediately captured in major news feeds.

FFIE

Faraday Future Intelligent Electric Inc.Consumer Cyclical

$1.21−$0.20

-14.2%

NASDAQ · Mkt cap $236 M

No news headlines were found in the last 48 hours to explain the 14.18% decline in FFIE. The drop likely reflects broader market sentiment, technical selling, or undisclosed company developments not yet captured in major news feeds.

Faraday Future is a pre-revenue or early-stage EV manufacturer with a history of volatility, capital constraints, and execution challenges. In the absence of any reported news catalyst, the decline could stem from several typical drivers for this class of stock: technical selling or stop-loss triggers following prior momentum loss, sector-wide EV weakness, funding concerns or insider signals about capital runway, competitive pressures in the EV space, or delayed delivery milestones. Because no headlines appeared in the 48-hour window, it is also possible that the move preceded news publication, was triggered by social media or rumor, or reflects accumulated negative sentiment that crystallized without a single discrete catalyst. This level of intraday volatility is not unusual for micro-cap or distressed growth stocks.

PLUT

Plutus Financial Group Limited Ordinary SharesFinancial Services

$2.15−$0.35

-14.0%

NASDAQ · Mkt cap $42 M

No news headlines were found in the last 48 hours for PLUT, so the 14% intraday decline cannot be attributed to a specific disclosed event. The drop likely reflects either technical selling pressure, a delayed market reaction to earlier news, or broader sector headwinds.

The absence of any recent news headlines makes it impossible to pinpoint a direct catalyst for the 14% decline on September 30, 2026. This is a significant one-day loss for a financial services stock, yet no earnings release, guidance change, regulatory action, acquisition news, or management announcement appears in the available sources as of the snapshot date. Possible explanations include technical factors such as profit-taking after a prior rally, momentum-driven selling, or a delayed market reaction to news published before the 48-hour window. For a financial services company like Plutus Financial Group, declines can also reflect broader sector rotation, credit market stress, or idiosyncratic company developments not yet widely reported.

TULP

Bloomia Holdings, Inc.

$2.50−$0.40

-13.8%

GMEX

GMEX ROBOTICS CORPORATION Class ATechnology

$2.71−$0.43

-13.7%

NASDAQ · Mkt cap $1.0 M

No news headlines were published in the last 48 hours about GMEX, so the 13.69% decline cannot be directly attributed to a disclosed event; the drop likely reflects market sentiment, technical selling, or non-public information.

The absence of recent news headlines makes it impossible to pinpoint a specific catalyst for GMEX's sharp 13.69% decline. For a small-cap robotics company trading at $2.71, typical drivers of single-day drops include disappointing quarterly results or forward guidance, loss of a major customer or contract, insider selling, short-seller reports, broader sector weakness in robotics or automation, or simple technical breakdown from accumulated selling pressure. Without access to intraday developments, earnings surprises, or sector-wide moves, we cannot distinguish between these possibilities. The stock's position as the 49th biggest loser suggests meaningful institutional or retail outflow rather than a micro-cap anomaly.

WETO

Webus International Limited Ordinary SharesTechnology

$1.01−$0.18

-13.6%